Tempus AI Climbs to 48th Most Actively Traded on FDA Approval and Revised Guidance Amid $1.19 Billion Volume Rally

On August 21, 2025, Tempus AI (TEM) surged 4.68% to $76.71, closing as the 48th most actively traded stock with a $1.19 billion volume. The rally followed a narrowed Q2 non-GAAP net loss and a revenue increase, alongside an upgraded 2025 guidance. FDA clearance for its Tempus ECG-Low EF software bolstered investor confidence, highlighting the company’s role in AI-driven precision medicine.

Strategic moves by Templeton Emerging Markets Investment Trust, including consistent share repurchases, contributed to capitalization stability and a modest price lift. While the stock’s recent volatility—sliding from $78.45 to $73.08 in two days—reflected market jitters, its closing at $75.12 signaled resilience amid broader financial challenges, including a high debt-to-equity ratio and negative return metrics.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to 2025 yielded a 7.61% total return with a 1.98% average daily gain. A Sharpe ratio of 0.94 indicated favorable risk-adjusted performance, though a -29.16% maximum drawdown underscored its sensitivity to market downturns.